Related Experiment Video
Updated: Apr 20, 2026
08:23
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
10.5K
Emerging drugs for sickle cell anemia.
Priya C Singh1, Samir K Ballas
1Bayhealth Cancer Institute, Hematology/Oncology , Dover, DE , USA.
Expert Opinion on Emerging Drugs
|November 29, 2014
Summary
Hydroxyurea is the only approved drug for sickle cell disease (SCD), but many patients do not respond or experience side effects. Emerging therapies offer new hope for treating this complex blood disorder.
Area of Science:
- Hematology
- Pharmacology
- Genetics
Background:
- Sickle cell disease (SCD) treatment has focused on hydroxyurea (HU) for over 50 years.
- HU is effective for some SCD patients, preventing complications like vaso-occlusive crises and acute chest syndrome.
- However, 25% of sickle cell anemia (SCA) patients do not respond to HU, and some experience severe side effects.
Purpose of the Study:
- To review the pathophysiology of SCD.
- To analyze current and emerging pharmacologic therapies for SCA.
- To highlight the need for novel, individualized treatments.
Main Methods:
- Comprehensive literature search across multiple databases (Medline, Embase, Cochrane, Scopus).
- Analysis of existing and investigational drug therapies for SCD.
- Review of the underlying mechanisms and pathophysiology of SCA.
Main Results:
- Hydroxyurea remains the primary FDA-approved therapy for SCD.
- A significant portion of patients exhibit resistance or intolerance to HU.
- Numerous new therapeutic agents targeting diverse pathways are under investigation.
Conclusions:
- SCD is a complex, heterogeneous disease with significant global impact.
- There is a critical need for more effective, personalized, and affordable treatments.
- Ongoing research focuses on novel therapies addressing multiple facets of SCD pathophysiology.
Keywords:
clinical trialsemerging drugshydroxyureapreventative therapysickle cellsickle cell anemiasickle cell diseasesickle cell therapysickle cell treatmentMore Related Videos
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
2.0K
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
20.7K
Related Concept Videos
01:22iPS Cell Differentiation
3.3K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.3K
01:22Bone Marrow Sampling and Transplants
2.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
588
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
588
01:27Combined Effects of Drugs: Synergism
8.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
8.0K
01:10Drugs that Destabilize Microtubules
4.4K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
01:29Pharmacogenomics: Identification of New Drug Targets
108
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108